Relevance of a national forecast growth rate as a regulation tool of the expensive hospital drug spending in France

MONNIER R, DEGRASSAT-THEAS A, PARENT DE CURZON O, SINEGRE M UF Études Médico-Economiques et Référentiels, Service Evaluations Pharmaceutiques et Bon Usage, AGEPS, AP-HP Objective In France, a forecast growth rate in spending related to the list of expensive hospital drugs, funded in addition to DRG-based payment, is determined annually (2% in 2012) If hospitals exceed […]